In addition, the upregulation of Nrf2 signaling limits NF-κB activation, leading to inhibition of the excessive production of pro-inflammatory cytokines and chemokines, thereby mitigating signs of pulmonary inflammation (Mohamed et al., 2021). The gene discussed is NFKB1; the disease is inflammatory response.